What a Healthcare Diagnostic Tool actually does
Surfaces clinical decision support by matching patient data to current guidelines for licensed clinician review — without making specific diagnostic recommendations that would trigger FDA SaMD classification.
The category is definitionally split by FDA regulatory status. A tool that outputs 'patient X may have condition Y' or 'consider medication Z' is Software as a Medical Device (SaMD) under the 21st Century Cures Act, almost certainly requiring 510(k) review (Class II clearance). Per JAMA Network Open (Sivakumar et al., 2025), 97% of AI/ML medical devices were cleared via the 510(k) pathway, with 295 FDA AI/ML clearances in 2025 alone. The safe scope for any non-device product is clinical decision support that (a) displays the basis of recommendations transparently so a licensed clinician can independently verify them, and (b) is used only by or for clinicians, never directly by patients.
The Texas AG's 2024 settlement with Pieces Technologies — over hallucination-rate accuracy claims in a clinical-AI product — is the enforcement signal that honesty in clinical AI claims is now a regulated matter, not just an ethical one. Foundation model for the safe CDS scope is Claude Opus 4.7 or GPT-5.5 via AWS Bedrock under BAA with per-call zero-data-retention. The model is the easy part. The hard parts are FDA submission ($25K–$250K+), clinical validation studies ($50K–$500K), and a Predetermined Change Control Plan (PCCP, August 2025 final guidance) for future model updates without new 510(k) submissions.
AI capabilities involved
Clinical decision support — guideline matching for clinician review (not patient-facing diagnosis)
Medical literature retrieval and summarization (PubMed RAG)
ICD-10/CPT auto-coding from clinician notes (revenue-cycle, not diagnostic)
Differential-diagnosis brainstorming for clinician review (never patient-facing)
Triage support for nurse-line workflows with escalation paths
Who uses this
- Established health systems with clinical-informatics teams and retained regulatory counsel
- FDA-experienced digital-health startups with prior device submission experience
- EHR vendors (Epic, Cerner, athenahealth) adding AI decision-support modules
- Telehealth platforms with licensed clinicians in the loop for triage support
- Revenue-cycle management vendors adding AI ICD-10/CPT auto-coding (revenue-cycle is not diagnostic)
SaaS alternatives on the market
Real products you can sign up for today — with current 2026 pricing, honest pros and cons.
Wellifiy
Wellness and wellbeing features adjacent to clinical workflows — not for diagnostic AI.
None
Quote-based
Pros
- +ISO 27001, HIPAA, GDPR, and PIPEDA certifications.
- +The closest WL platform to a clinical-adjacent health product.
- +Includes clinician-workflow modules.
Cons
- −Does not extend to diagnostic AI — stops short of any diagnostic claim.
- −Quote-based with no public pricing.
- −Not FDA-cleared for any diagnostic indication.
The AI stack
The CDS stack requires BAA-covered foundation models at every layer, with per-call zero-data-retention enforced at the inference gateway. The hardest engineering challenge is the independent cite-verification layer — every CDS recommendation must display its guideline source so the clinician can verify independently, which requires a medically curated RAG corpus and retrieval quality that general-purpose vector search does not provide.
Foundation model (CDS reasoning)
Matches patient data to current clinical guidelines and generates differential-diagnosis options for clinician review — never patient-facing, always with source citations.
Claude Opus 4.7 via AWS Bedrock
$5 input / $25 output per M tokensComplex CDS queries where reasoning depth directly affects clinical safety.
GPT-5.5 via Azure OpenAI
$5 input / $30 output per M tokensEU-market deployments requiring EU data residency under GDPR and EU MDR.
Our pick: Claude Opus 4.7 via Bedrock for US deployments; GPT-5.5 via Azure for EU. Never use consumer-tier Claude.ai or ChatGPT with any real patient data.
Medical RAG corpus
Provides the verified clinical guideline sources that the AI must cite and display to the clinician for independent review.
text-embedding-3-large via Azure (HIPAA-eligible)
$0.13/M tokensProduction medical RAG over PubMed, UpToDate, local guideline corpus.
Our pick: Embed PubMed abstracts + local clinical guideline corpus using text-embedding-3-large via Azure. Update the corpus quarterly or when major guidelines are revised. Cache embeddings — never re-embed the full corpus on every query.
Specialized clinical model (optional)
Domain-specific fine-tuned model for clinical tasks where general-purpose LLMs underperform.
Google MedLM via Vertex AI
Custom pricing via Google CloudHealth systems already running GCP infrastructure where MedLM's clinical training provides measurable quality uplift over general LLMs.
Our pick: Evaluate MedLM against Claude Opus 4.7 on your specific clinical use case before committing to the Google Cloud dependency. MedLM's advantage is domain-specific fine-tuning; Opus 4.7's advantage is general reasoning strength and lower cost.
Reference architecture
The CDS pipeline is a request-retrieval-verify loop: every CDS query retrieves guideline evidence from the RAG corpus, the model reasons over it and generates a recommendation with explicit source citations, and an independent verification step confirms the cited guidelines exist and match the model's summary. The clinician sees both the recommendation and the full source text — enabling independent verification as required by FDA's non-device CDS criteria.
Clinician submits a patient scenario or structured data query
Clinician-facing dashboard (not patient-facing)Clinician inputs: relevant patient demographics, presenting symptoms, existing diagnoses, current medications. Patient identifying data is de-identified before leaving the EHR layer.
Query routed to inference gateway with BAA + ZDR enforced
AWS Bedrock inference gateway (Lambda + API Gateway)Every request includes ZDR header. Session hash logged to CloudTrail audit store. Gateway rejects any call missing the ZDR flag.
Medical RAG retrieves relevant guideline evidence
Supabase pgvector (Azure-hosted HIPAA-eligible embeddings)Query is embedded and used to retrieve top 5 guideline passages from PubMed + UpToDate + local clinical corpus. Retrieved passages include source title, publication date, and DOI for the clinician to verify.
Claude Opus 4.7 generates CDS output with citations
AWS Bedrock (Claude Opus 4.7)Prompt includes: patient scenario, retrieved guideline passages, and strict system prompt: 'You are providing clinical decision support for a licensed clinician. Display the source of every recommendation. Never make a definitive diagnosis. Frame all outputs as considerations for clinician review.' Output: structured JSON with recommendations + source citations.
Independent cite-verification step
Citation verification service (PubMed API + DOI lookup)Each cited source is verified against PubMed or the local guideline corpus. Unverifiable citations are flagged and removed from the clinician's view. This is the Mata v. Avianca lesson applied to clinical AI.
CDS recommendation presented to clinician with full source access
Clinician dashboardClinician sees the recommendation, confidence indicators, and the full text of each cited guideline. The clinician can click through to the original source. The interface explicitly labels this as 'AI-assisted decision support — for clinician review.'
Audit log records every query and CDS output
AWS CloudTrail + S3Immutable record of: query hash, model version, guideline sources retrieved, recommendation generated, and clinician ID. Required for HIPAA compliance and FDA post-market surveillance.
Estimated cost per request
~$0.12–$0.40 per CDS query (Opus 4.7, 4–8K tokens with RAG context); ~$0.05 per citation verification call; FDA-mandated audit logging adds ~$0.01 per query in CloudTrail + S3 costs.
Cost calculator
Drag the sliders to model your actual usage. The numbers update in real time so you can stress-test economics before writing a single line of code.
CDS query volume at a health system or telehealth platform. Note: the AI API cost is the smallest budget line item here — regulatory, legal, and validation costs dwarf infrastructure.
Estimated monthly cost
$1,375
≈ $16.5k per year
Calculator notes
- At 5,000 CDS queries/mo, total AI API cost is ~$900/mo — manageable for a health system context.
- This calculator does NOT include FDA submission costs ($25K–$250K), clinical validation ($50K–$500K), or regulatory consultant fees ($5K–$50K/yr).
- PubMed API is free for non-commercial use; UpToDate requires a commercial license (~$600/yr per seat) for production clinical use.
- PCCP (Predetermined Change Control Plan) compliance for model updates adds ongoing regulatory documentation overhead.
Build it yourself with vibe-coding tools
A Lovable + Anthropic prototype is appropriate for internal research, IRB-approved studies, and investor demos only. It must display an explicit 'This is a research prototype, not a cleared medical device, and is not for patient care' disclaimer on every screen. Never collect real patient data on a prototype.
Time to MVP
12–16 hours (demo/research prototype only)
Total cost to MVP
$25 Lovable Pro + $40 API credits (demo only)
You'll need
Starter prompt
Build a CLINICAL DECISION SUPPORT RESEARCH PROTOTYPE using React, Supabase, and Anthropic Claude Sonnet 4.6. IMPORTANT: This prototype is for internal research and investor demos ONLY. Every screen must display: 'RESEARCH PROTOTYPE — Not FDA-cleared. Not for patient care. For internal evaluation only.' Core features (demo scope): 1. Clinician query input: structured form (patient demographics, presenting complaint, existing conditions, current medications). No real patient names or IDs. 2. PubMed RAG simulation: embed a curated set of 50 clinical guidelines (hardcoded JSON for demo) into Supabase pgvector. Retrieve top 3 relevant guidelines per query. 3. CDS output display: Edge Function calls Claude Sonnet 4.6 with the query + retrieved guidelines. System prompt: 'You are a clinical decision support tool for licensed clinicians. For every recommendation, cite the specific guideline source. Never make a definitive diagnosis. Frame all outputs as considerations for clinician review.' Display recommendation + source citations. 4. Citation display: show the full text of each cited guideline passage below the recommendation. Label: 'Clinician must independently verify each recommendation against the cited source.' 5. Disclaimer: full-screen modal on first load: 'This is a research prototype. It is NOT a cleared medical device. It is NOT for clinical use. Patient data must NEVER be entered.' Requires explicit acknowledgment. Data model: queries (id, scenario_text, retrieved_guidelines jsonb, cds_output text, created_at) — no patient identifying information. Style: clinical, minimal, black/white with red disclaimer banners.
Paste this into Lovable
Follow-up prompts (run in order)
- 1
Add a real PubMed API integration (NCBI E-utilities, free for non-commercial use): replace the hardcoded guideline JSON with live PubMed abstract retrieval based on the clinical query. Embed retrieved abstracts in real-time and display their PubMed IDs with links to the full articles.
- 2
Add a citation verification mock: for each cited guideline, show a green 'Verified' badge if the citation text matches the retrieved source, or a red 'Unverified — manual review required' badge if it does not. This demonstrates the Mata v. Avianca safeguard to investors.
- 3
Add a Bedrock stub: show the architecture diagram to investors — AWS Bedrock would replace the direct Anthropic API call in production, enforcing BAA + ZDR. Display a modal: 'In production, all calls route through AWS Bedrock with a Business Associate Agreement and per-call zero-data-retention enforcement.'
Expected output
A research prototype demonstrating the CDS architecture — guideline retrieval, AI-assisted recommendations with source citations, and clinician-independent-verification UX — suitable for internal evaluation and investor demonstrations. Not suitable for any patient care.
Known gotchas
- !Any use of real patient data in a prototype without FDA clearance, a signed BAA, and IRB approval exposes you and your organization to FDA enforcement and HIPAA penalties.
- !The Mata v. Avianca pattern (LLM fabricating citations) is a critical failure mode for clinical AI — always verify that cited guidelines actually exist and say what the model claims.
- !Google MedLM, Anthropic, and OpenAI all update their models — a PCCP (Predetermined Change Control Plan) is required for any model update to a cleared device to avoid a new 510(k) submission.
- !EU deployment requires CE-marking under EU MDR and post-market surveillance — a separate regulatory process from FDA 510(k). Plan for both if EU launch is in scope.
Compliance & risk reality check
Healthcare diagnostic AI carries the heaviest regulatory burden in the entire project. FDA SaMD classification, HIPAA BAA requirements, FTC accuracy-claim enforcement, and EU high-risk AI classification all intersect here with real enforcement precedent.
FDA SaMD — 510(k) review for diagnostic outputs
Any AI software that makes specific diagnosis or treatment recommendations is Software as a Medical Device under the 21st Century Cures Act. Per JAMA Network Open (Sivakumar et al., 2025), 97% of AI/ML medical devices are cleared via 510(k), taking 6–18 months at $25K–$250K+ in submission costs. The non-device CDS exemption requires that the software displays its reasoning basis transparently so a licensed clinician can independently verify it, AND is used only by or for clinicians. FDA's revised CDS guidance (January 2026) narrowed this exemption.
Mitigation: Retain a healthcare regulatory consultant before any code is written. Scope the product to non-device CDS (guideline matching + recommendation with full source display) rather than diagnostic output. If any diagnostic functionality is required, budget for 510(k) submission from day one.
HIPAA BAA + per-call zero-data-retention
Any LLM handling PHI (including patient symptom data, demographic data used in context of care) requires a signed BAA with the model provider. AWS Bedrock added to HIPAA-eligible services list February 2026. Per-call ZDR must be enforced at the inference gateway — not in application code where it is routinely misconfigured.
Mitigation: Route all production model calls through AWS Bedrock or Azure OpenAI under a signed DPA/BAA. Enforce ZDR headers at a dedicated gateway Lambda. Audit every call to CloudTrail.
FTC Section 5 + Texas AG accuracy-claim precedent (Pieces Technologies)
The Texas AG's 2024 settlement with Pieces Technologies over a clinical-AI hallucination-rate accuracy claim established that overstating AI accuracy in clinical contexts triggers consumer-protection enforcement. Any marketing claim about the AI's diagnostic accuracy, sensitivity, or specificity must be validated in clinical studies and accurately represented.
Mitigation: All marketing copy must accurately represent the AI's clinical performance, validated by published or submitted clinical validation studies. 'AI-powered diagnostic tool' without published accuracy data is an enforcement risk.
EU AI Act Annex III — high-risk medical AI (CE-marking required)
Medical AI is explicitly listed as high-risk under EU AI Act Annex III. For EU deployment, this requires conformity assessment, post-market surveillance documentation, and registration in the EU AI database before deployment. EU MDR also applies for diagnostic software intended for patients.
Mitigation: Engage a EU notified body before any EU launch planning. CE-marking under EU MDR and EU AI Act conformity assessment are separate processes that must both be completed.
Predetermined Change Control Plan (PCCP) — August 2025 final guidance
FDA's August 2025 final guidance on PCCP allows AI/ML-based SaMD to update their models without a new 510(k) submission, provided the PCCP is approved as part of the initial submission. Without an approved PCCP, every model update potentially requires a new 510(k).
Mitigation: Include PCCP in the initial 510(k) submission plan. Work with your regulatory consultant to define the scope of permissible model updates, performance monitoring protocols, and transparency reporting requirements.
Build vs buy: the real math
24–52 weeks (software only, excluding FDA)
Custom build time
$80,000–$250,000+
One-time investment
Depends on the clinical indication and reimbursement/licensing model
Breakeven vs buying
The build economics for clinical AI are unlike any other category in this project. Software cost ($80K–$250K) is typically the smallest budget line item. FDA 510(k) submission adds $25K–$250K and 6–18 months. Clinical validation studies (required for a credible submission) add $50K–$500K. A realistic all-in budget for a specific clinical AI tool from concept to FDA clearance is $200K–$1M+ over 2–3 years. The revenue model that justifies this is typically health-system licensing ($50K–$200K/yr per site) or per-use reimbursement via CPT codes (if CMS adds coverage for the specific AI application). This is a venture-backed or health-system-funded category, not a solo-founder category.
Skip the DIY — RapidDev builds the production version
A Lovable MVP gets you a demo. Production needs auth that doesn't leak data, AI calls that don't bankrupt you, observability when models drift, and code you can audit. That's what we ship.
Discovery call (free)
30 minWe map your exact Healthcare Diagnostic Tool use case: who uses it, target volume, AI model choice, integrations, compliance scope. You get a detailed scope document and fixed-price quote within 48 hours.
AI-accelerated build
24–52 weeks (software only, excluding FDA)Our engineers use Claude Code, Lovable, and custom tooling to ship 3–5x faster than agencies. You see weekly progress in a staging environment — not a black box.
Launch + handoff
1 weekWe deploy to your infrastructure, transfer the GitHub repo, set up CI/CD and monitoring, and train your team. You own 100% of the source code, prompts, and model configurations.
What you get
Timeline
24–52 weeks (software only, excluding FDA)
Investment
$80,000–$250,000+
vs SaaS
ROI in Depends on the clinical indication and reimbursement/licensing model
30-min call. Fixed-price quote within 48 hours. No commitment.
Frequently asked questions
How much does it cost to build a white-label AI healthcare diagnostic tool?
$80,000–$250,000 for the software alone with RapidDev. FDA 510(k) submission adds $25,000–$250,000+. Clinical validation studies add $50,000–$500,000. Realistic all-in budget from concept to FDA-cleared product: $200,000–$1,000,000+ over 2–3 years. This is a venture-backed or health-system-funded category — not a solo-founder category.
How long does it take to ship?
24–52 weeks for the software alone, excluding FDA timeline. FDA 510(k) review adds 6–18 months. Total from concept to cleared product: typically 2–3 years. The software timeline and the FDA timeline overlap partially — you can begin the submission process while the software is being built, but you cannot launch clinically until clearance is granted.
Can RapidDev build this for my health system?
Yes, for the software component. RapidDev has built 600+ applications including HIPAA-covered infrastructure. However, we strongly recommend engaging a healthcare regulatory consultant before scoping the software — the regulatory pathway (510(k) vs. non-device CDS) directly determines the software architecture. Book a free 30-minute consultation.
When does AI clinical software require FDA clearance?
When it makes specific diagnostic or treatment recommendations. FDA's January 2026 revised CDS guidance defines the non-device exemption narrowly: the software must display the basis of its recommendations so a clinician can independently verify them, AND must be used only by or for clinicians. Any consumer-facing AI that interprets symptoms and suggests conditions is almost certainly SaMD requiring 510(k).
What is the Pieces Technologies settlement and why does it matter?
The Texas AG settled with Pieces Technologies in 2024 over accuracy claims for a clinical AI product that had a higher hallucination rate than advertised. The settlement established that overstating clinical AI accuracy is a consumer-protection violation enforceable by state AGs, not just an ethical issue. Any marketing claim about diagnostic accuracy must be validated in published clinical studies and accurately represented.
What is a non-device CDS product, and is that a safe alternative to a diagnostic tool?
Non-device clinical decision support software matches patient data to current clinical guidelines and displays the full source basis for a licensed clinician to independently verify. It is not patient-facing and does not make specific diagnostic recommendations. FDA's January 2026 guidance identifies four criteria that must all be met for the non-device exemption: not intended for diagnosis/treatment; displays the basis for recommendation; clinician can independently review the basis; intended only for use by or for clinicians. This is the safe scope for a custom CDS build — but it still requires HIPAA BAA and a regulatory consultant review.
Want the production version?
- Delivered in 24–52 weeks (software only, excluding FDA)
- You own 100% of the code
- AI cost monitoring built in
30-min call. No commitment.
